Serum Her-2/neu and Survivin Levels and Their Relationship to Histological Parameters in Early-stage Breast Cancer

Author： Goksel G   Taneli F   Uslu R   Ulman C   Dinc G   Coskun T   Kandiloglu AR  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.35, Iss.2, 2007-03, pp. : 165-172

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L.   Keam Susan J.  

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite

Serum HER-2/neu Extracellular Domain Levels in Men Presenting with Suspected Prostate Cancer

By Croal B.L.   Mitchell I.D.C.   Mutch W.J.   Dickie A.   Cohen N.   Ross I.S.  

UroOncology, Vol. 2, Iss. 2, 2002-01 ,pp. : 99-102

Ashgate Publishing Ltd

Access to resources Recommend Favorite

HER2/neu (E75) vaccine reduces breast cancer recurrence

By  

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?

By Paplomata Elisavet   Nahta Rita   O'Regan Ruth M.  

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 517-526

Blackwell Publishing

Access to resources Recommend Favorite

Early breast cancer patients with low levels of HER2 expression benefit more from the cancer vaccine E75

By  

Inpharma, Vol. 1, Iss. 1635, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite